Roman P.
- Country
- Germany
- Department
- Herzzentrum Med. Klinik III
Research Overview
- Phase IIb Randomized Double‑Blind Placebo‑Controlled Study of Eplontersen Plus ALXN2220 Versus Eplontersen + Placebo in Adults with Transthyretin‑Mediated Amyloid Cardiomyopathy
- Evaluation of Mavacamten in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy: A Randomized, Double-blind, Placebo-controlled Study
- Efficacy and Safety Evaluation of ALXN2220 in Adult Patients with Transthyretin Amyloid Cardiomyopathy: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Data & Insights
Has run more than one trial at 110 of 204 partner sites.
Specializations
Cardiomyopathy Specialization
This investigator demonstrates significant expertise in treating various forms of cardiomyopathy, with particular focus on Transthyretin Amyloid Cardiomyopathy (ATTR-CM) and Non-obstructive Hypertrophic Cardiomyopathy.
- ATTR-CM Management
- Hypertrophic Cardiomyopathy Treatment
- Cardiac Function Assessment
The investigator's work encompasses innovative therapeutic approaches for these complex cardiac conditions.
Takotsubo Syndrome Research
The investigator has specialized knowledge in Takotsubo syndrome, exploring novel therapeutic interventions including the application of Cyclosporine A for treating this cardiac condition.
- Myocardial Damage Assessment
- Troponin Level Analysis
- Cardiac Biomarker Studies
Their research involves detailed evaluation of myocardial injury markers and therapeutic outcomes in Takotsubo syndrome patients.
Therapeutic Innovation
The investigator focuses on evaluating novel treatments for cardiac conditions, including research into mavacamten and other therapeutic agents for cardiac disorders.
- Exercise Capacity Assessment
- Patient Health Status Evaluation
- Cardiovascular Clinical Events
Their work includes comprehensive assessment of patient outcomes and treatment efficacy in cardiovascular conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.